SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs(India) - Quaterly Results

11 Feb 2025 Evaluate
The Turnover for the quarter ended December 2024 of Rs. 465.13 millions increase by 56.27% from Rs. 297.65 millions.The company has announced a 25.17% increase in its profits to Rs . 68.82  millions for the  quarter ended December 2024 compared to Rs. 54.98 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 104.88 millions compared to 74.13 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 465.13 297.65 56.27 1252.83 924.64 35.49 1315.99 1177.84 11.73
Other Income 23.70 33.95 -30.19 113.91 52.92 115.25 61.89 45.98 34.60
PBIDT 104.88 74.13 41.48 283.22 202.67 39.74 265.06 217.71 21.75
Interest 4.94 5.35 -7.66 14.04 13.39 4.85 19.08 9.85 93.71
PBDT 99.94 68.78 45.30 269.18 189.28 42.21 245.98 207.86 18.34
Depreciation 4.75 2.99 58.86 12.26 8.35 46.83 12.44 13.37 -6.96
PBT 95.19 65.79 44.69 256.92 180.93 42.00 233.54 194.49 20.08
TAX 26.37 10.81 143.94 59.10 41.64 41.93 57.79 37.32 54.85
Deferred Tax -2.29 -2.21 3.62 -3.82 -8.87 -56.93 -5.86 -4.66 25.75
PAT 68.82 54.98 25.17 197.82 139.29 42.02 175.75 157.17 11.82
Equity 160.82 160.82 0.00 160.82 160.82 0.00 160.82 155.82 3.21
PBIDTM(%) 22.55 24.91 -9.46 22.61 21.92 3.14 20.14 18.48 8.97

Kilitch Drugs(India) Share Price

134.90 -0.20 (-0.15%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×